HALISTER: Novartis Says 2017 FY Sales to Be Broadly in Line with Prior Yr

Novartis Says 2017 FY Sales to Be Broadly in Line with Prior Yr

(Bloomberg) -- Co. to buy back $5b of shares in 2017, according to statement on Wednesday.
  • For 2017, core operating profit to be “broadly in line with prior year to low single digit decline,” assuming constant currency
  • 4Q core EPS: $1.12 vs est. $1.13
  • 4Q sales: $12.32b vs est. $12.32b
  • 4Q core operating income (EBIT): $3.01b vs est. $3.02b
(estimates are continuing operations in local currency, not constant FX)
  • Webcast/conf call at 1pm CET
  • Statement
  • NOTE: Yesterday, PREVIEW NOVARTIS 4Q: Entresto Guidance, Alcon Seen in Focus
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
NOVN VX (Novartis AG)

To de-activate this alert, click here

UUID: 7947283